2020
DOI: 10.1016/j.cld.2020.01.012
|View full text |Cite
|
Sign up to set email alerts
|

Minimal Hepatic Encephalopathy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
27
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 31 publications
(27 citation statements)
references
References 32 publications
0
27
0
Order By: Relevance
“…In addition, the elevated serum S100B is an early marker of BBB disruption which might be prior to neuronal damage and can potentially affect therapeutic effects; this can be explained by the fact that astrocytes form part of the BBB and its increased permeability during hepatic encephalopathy (HE) due to acute liver failure can be partially correlated to impaired astrocytic functions (Kanner et al 2003). S100B is reported as a surrogate marker for diagnosing the mild cognitive impairment in cirrhotic patients prior to their advancement to HE (Saleh et al 2007), and MHE is the mildest stage of HE (Karanfilian et al 2020). Therefore, we hypothesized that over-expression of S100B occurred in MHE.…”
Section: Ym Task Y-maze Taskbackgroundmentioning
confidence: 97%
“…In addition, the elevated serum S100B is an early marker of BBB disruption which might be prior to neuronal damage and can potentially affect therapeutic effects; this can be explained by the fact that astrocytes form part of the BBB and its increased permeability during hepatic encephalopathy (HE) due to acute liver failure can be partially correlated to impaired astrocytic functions (Kanner et al 2003). S100B is reported as a surrogate marker for diagnosing the mild cognitive impairment in cirrhotic patients prior to their advancement to HE (Saleh et al 2007), and MHE is the mildest stage of HE (Karanfilian et al 2020). Therefore, we hypothesized that over-expression of S100B occurred in MHE.…”
Section: Ym Task Y-maze Taskbackgroundmentioning
confidence: 97%
“…What both terms have in common is that they refer to disturbances in the brain’s function. However, delirium is clinical, usually more acute disease entity that requires a rapid clinical response, whereas the disease entity encephalopathy, as is its nature, tends to develop slowly and sometimes only reveals subtle abnormalities, as in hepatic encephalopathy ( Wijdicks, 2016 ; Karanfilian et al, 2020 ) or drug-induced encephalopathy ( Hansen, 2012 ) including antiepileptic-drug-induced encephalopathy ( Hansen et al, 2010 ). Moreover, encephalopathies can also designate chronic brain states such as epileptic encephalopathies (for review, see Palmer et al, 2021 ) often sharing a genetic cause and encompassing a broad spectrum of developmental electroclinical syndromes characterized by subtle seizures and intellectual disabilities (like those caused by epileptic encephalopathies associated with KCNT1 mutations) ( Ohba et al, 2015 ; Hansen et al, 2017 ).…”
Section: Functionality Of the Locus Coeruleus In Deliriummentioning
confidence: 99%
“…These types of analysis require specialised software and skills; therefore, they are not routinely used in clinics. [32] 94.0 79.0 91.0 Simple <5 min [42] SPTs CFF [43] 61.0 79.0 84.0 Intermediate [42] 5-15 min [42] This was a meta-analysis ICT [44] 87.0 77.0 90.…”
Section: Detection Of Changes In Brain Physiologymentioning
confidence: 99%